


EMA: The European Medicines Agency; HIV: Human immunodeficiency virus; LMICs: low-income, lower middle-income and upper middle-income countries as per World Bank classification; PrEP: Pre-Exposure Prophylaxis; USFDA: The United States Food and Drug Administration



HIV: Human immunodeficiency virus; HTE: heavily treatment-experienced; LMICs: low-income, lower middle-income and upper middle-income countries as per World Bank classification; TLD: tenofovir, lamivudine and dolutegravir